Promising Penny Stocks To Consider In October 2026

In the last week, the market has stayed flat, but it is up 12% over the past year with earnings expected to grow by 17% per annum over the next few years. For investors willing to venture beyond the big names, penny stocks—often smaller or newer companies—can be full of surprises. While these stocks might seem like a relic from past market eras, they still offer a mix of affordability and growth potential when paired with strong financials.

Let's dive into some prime choices out of the screener.

Immuneering (IMRX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Immuneering Corporation is a late-stage oncology company focused on developing medicines for broad populations of cancer patients in the United States, with a market cap of approximately $236.79 million.

Operations: Immuneering Corporation has not reported any specific revenue segments.

Market Cap: $236.79M

Immuneering Corporation, with a market cap of approximately US$236.79 million, is a pre-revenue oncology company focused on developing treatments for cancer patients. Despite being unprofitable and not expected to achieve profitability in the next three years, the company has no debt and maintains sufficient cash runway for over a year. Recent data from its Phase 2a study showed promising results for its lead candidate, atebimetinib, in pancreatic cancer treatment by extending survival rates and preserving patient body mass. The ongoing Phase 3 MAPKeeper 301 trial further explores atebimetinib's potential benefits in combination with chemotherapy.

• Jump into the full analysis health report here for a deeper understanding of Immuneering.
• Assess Immuneering's future earnings estimates with our detailed growth reports.

Perfect (PERF)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Perfect Corp. is an artificial intelligence software as a service company offering AI and AR-powered solutions for the beauty, fashion, and skincare industries globally, with a market cap of approximately $201.66 million.

Operations: The company generates revenue of $71.07 million from its Internet Software & Services segment.

Market Cap: $201.66M

Perfect Corp., with a market cap of US$201.66 million, is advancing its position in AI and AR solutions for beauty and fashion industries. Recent product innovations include a generative AI upgrade to its AI Glasses Virtual Try-On solution, enhancing accuracy and performance. The company also partnered with LIERAC to offer an AI-powered skin diagnosis across Europe, integrating seamlessly into e-commerce platforms. Despite negative earnings growth last year, Perfect Corp.'s debt-free status and strong short-term asset coverage provide financial stability. However, the company's return on equity remains low at 3.7%, indicating room for improvement in profitability metrics.

• Click here and access our complete financial health analysis report to understand the dynamics of Perfect.
• Gain insights into Perfect's outlook and expected performance with our report on the company's earnings estimates.

Ready Capital (RC)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Ready Capital Corporation operates as a real estate finance company in the United States with a market cap of $191.99 million.

Operations: The company's revenue segments include Small Business Lending generating $61.06 million and LMM Commercial Real Estate with -$372.51 million.

Market Cap: $191.99M

Ready Capital Corporation, with a market cap of US$191.99 million, faces challenges as it is currently unprofitable with a negative return on equity of -40.68%. The company reported significant net losses for the second quarter and first half of 2026, totaling US$101.53 million and US$303.26 million respectively. Despite high debt levels, its short-term assets exceed liabilities by a substantial margin. Revenue from small business lending is overshadowed by losses in commercial real estate operations. Recent dividend declarations indicate ongoing shareholder returns, although common stock dividends remain minimal at $0.01 per share for the third quarter of 2026.

• Click to explore a detailed breakdown of our findings in Ready Capital's financial health report.
• Understand Ready Capital's earnings outlook by examining our growth report.

Taking Advantage

• Embark on your investment journey to our 323 US Penny Stocks selection here.
• Ready To Venture Into Other Investment Styles? This technology could replace computers: discover the 25 stocks are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com